Publications
5677 Results
- Journal / Conference
- JTO Clinical and Research Reports Oct 16;5(12):100738
- Year
- 2024
- Research Committee(s)
- Lung
- PMID
- PMID39619274
- PMC
- PMC11605468
- Study Number(s)
- S1701
S1701, A randomized phase II trial of carboplatin-paclitaxel with and without ramucirumab in patients with locally advanced, recurrent, or metastatic thymic carcinoma
- Journal / Conference
- JNCI-Journal of the National Cancer Institute May 8;116(5):673-680
- Year
- 2024
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- PMID
- PMID38243705
- PMC
- PMC11077308
- Study Number(s)
- S1609
Correlation between tumor size change and outcome in a rare cancer immunotherapy basket trial
- Journal / Conference
- ESMO (September 13-17, 2024, Barcelona, Spain), poster
- Year
- 2024
- Research Committee(s)
- Breast
- Study Number(s)
- CTSU/A011401
Effect of a weight loss intervention (WLI) on exercise behaviors in women with breast cancer: Results from the Breast Cancer Weight Loss (BWEL) Trial
- Journal / Conference
- ASTRO Annual Meeting (September 29 - October 2, 2024, Washington, DC), Quick Pitch Oral Presention; International Journal of Radiation Oncology, Biology, Physics Volume 120:Number 2S
- Year
- 2024
- Research Committee(s)
- Lymphoma
Beyond Involved-Site Radiotherapy: NRG, COG, ALLIANCE, ECOG, SWOG, and CCTG Consensus Nomenclature for Radiation Targets on NCTN Lymphoma Trials
- Journal / Conference
- IGCS Meeting (October 16-18, 2024 Dublin, Ire), poster
- Year
- 2024
- Research Committee(s)
- Palliative Care
- Study Number(s)
- S1316
Evaluation of a prognostic scoring system among patients in the Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction Study (SWOG 1316)
- Journal / Conference
- ASCO Quality of Care Symposium (September 27-28, 2024, San Francisco, CA), poster;JCO Oncol Pract 20, 2024 (suppl 10; abstr 320)
- Year
- 2024
- Research Committee(s)
- Cancer Care Delivery
- Study Number(s)
- S2108CD
Utilization of genomic tumor testing (GTT) among community oncologists participating in SWOG S2108CD
- Journal / Conference
- ASCO Quality of Care Symposium (September 27-28, 2024, San Francisco, CA), poster; JCO Oncol Pract 20, 2024 (suppl 10; abstr 10)
- Year
- 2024
- Research Committee(s)
- Cancer Care Delivery
The Cost of Doing Business – Drug Costs in Federally-Sponsored Cancer Clinical Trials
- Journal / Conference
- SITC (Nov. 6-10, Houston, TX), poster
- Year
- 2024
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- Study Number(s)
- S1609
Correlations Between Baseline Tumor Burden and Overall Survival in Patients with Rare Cancers Treated with Immune Checkpoint Inhibitors (NCI/SWOG S1609)
- Journal / Conference
- ISHL (October 26-28, Cologne, Germany), oral
- Year
- 2024
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S1826
Progression-Free Survival (PFS) with Nivolumab-AVD is superior to Brentuximab Vedotin-AVD with 2-year follow-up of S1826 in Pediatric Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL)
- Journal / Conference
- ISHL (October 26-28, Cologne, Germany), oral
- Year
- 2024
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S1826